Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Venetoclax in AML
NCT01994837Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoint: Objective Remission Rate at 12 weeks. Started Nov 2013; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01994837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994837.